Skip to main content
main-content

Lung and thoracic cancers

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

medwireNews top story

CTCs prognostic in limited-stage SCLC

Cancer cells

The circulating tumor cell count can identify patients with limited-stage small-cell lung cancer who are likely to have poor survival outcomes despite treatment, report researchers who have identified 15 cells per 7.5 mL as the optimal cutoff.

medwireNews top story

Whole-body MRI staging quicker and cheaper than standard pathways in NSCLC

Patient in MRI scanner

The Streamline L trial has found that in patients with newly diagnosed non-small-cell lung cancer, a staging pathway using whole-body magnetic resonance imaging has similar accuracy but a shorter time to complete staging and lower mean per-patient costs versus standard pathways.

medwireNews top story

Immunotherapy-related AEs reviewed, underlying mechanism postulated

Cancer cell

Researchers have comprehensively analyzed the incidence of adverse events in trials of PD-1 and PD-L1 inhibitors, while another team has provided insight into the potential pathophysiologic process underlying these effects.

Expert opinion

Immunotherapy for patients with metastatic NSCLC harboring an EGFR mutation

DNA samples

Management of EGFR-mutant non-small-cell lung cancer has been dominated by targeted therapies, but it is less clear where immunotherapy will fit into the treatment paradigm. Charu Aggarwal (University of Pennsylvania, USA) explores the current place of immunotherapy in treating this disease.

Expert opinion

Management of EGFR mutation-positive NSCLC: Two steps forward, looking back

Adenocarcinoma histology

Caroline McCoach (Helen Diller Family Comprehensive Cancer Center, CA, USA) and Howard (Jack) West (Swedish Cancer Institute, WA, USA) discuss the way forward after great progress with tyrosine kinase inhibitors targeting the epidermal growth factor receptor in non-small-cell lung cancer.

Expert opinion

Choosing an immunotherapy approach in patients with advanced NSCLC

Advanced NSCLC

Liza Villaruz (Hillman Cancer Center, PA, USA) examines recent KEYNOTE trials investigating pembrolizumab for advanced non-small-cell lung cancer and the questions they raise regarding patient selection and combination therapy.

View from the clinic

Explaining immunotherapy to our patients with NSCLC

Explaining immunotherapy

Immunotherapy is changing practice in lung cancer, and with this, patient education. In this 'View from the clinic' article, Advisory Board member Beth Eaby-Sandy (Abramson Cancer Center, PA, USA) describes how she explains the new immunotherapy treatments to her patients. 

28-02-2019 | Lung cancer | At a glance | Article

At a glance: CheckMate lung cancer trials

Here we round up the CheckMate trials evaluating the PD-1 inhibitor nivolumab in non-small-cell lung cancer and small-cell lung cancer.

28-01-2019 | Immunotherapy | Podcast | Audio

Understanding the relationship between the gut microbiome and immunotherapy

Jennifer Wargo, from The University of Texas MD Anderson Cancer Center in Houston, USA, shares her insights into recent research showing an association between intestinal microbiota and response to immunotherapy (13:27).

12-12-2018 | Immunotherapy | Feature | Article

Hyperprogression as a response to immunotherapy: ‘A serious downside’

In light of recent reports of hyperprogression in response to treatment with cancer immunotherapy, medwireNews spoke to medical oncologist Razelle Kurzrock (University of California, San Diego, La Jolla, USA) about the phenomenon, the implications for therapy, and future directions for research.

Our Editorial Board advisor

Fiona Blackhall MD, PhD

Dr Blackhall is a Professor of Thoracic Oncology with expertise in personalized medicine and circulating biomarkers within the Institute of Cancer Studies, University of Manchester and has been a Consultant Medical Oncologist at The Christie Hospital, Manchester since 2005. She has conducted over 50 therapeutic clinical trials, including practice-changing precision medicine studies, and led on new directions in radiotherapy-related research and supportive palliative care research.

Videos

22-10-2018 | Non-small cell lung cancer | ESMO 2018 | Video

Mechanisms of acquired resistance to osimertinib in AURA3

Vassiliki Papadimitrakopoulou outlines the candidate molecular mechanisms of acquired osimertinib resistance as revealed in the AURA3 trial and discusses the possibilities for later lines of treatment (4:12).

14-06-2018 | Lung cancer | ASCO 2018 | Video

Expert commentary: Lung cancer highlights, including the KEYNOTE-042 and CCGA studies

ASCO expert David Graham comments on the plenary KEYNOTE-042 trial, putting the findings in context of other recent research, and highlights the initial report from the CCGA study that could pave the way for a novel lung cancer screening approach. (5:02)

08-06-2018 | Lung cancer | ASCO 2018 | Video

Expert highlights: An update from ASCO 2018 on targeted therapies in lung cancer

Advisory Board member Ross Camidge takes us through the latest research on ALK inhibitors and other targeted therapies for lung cancer, including updated data from the ALEX trial (8:46).

Symposium scientific summaries

08-10-2018 | Lung cancer | Scientific summary | Collection

Steering improved outcomes in non-driver mutation lung cancer: Progress and challenges

The symposium discussed the latest in non-driver mutation lung cancer, from histologic and molecular profiling, through to current and emerging treatment options, including those for patients with refractory and aggressive disease. The objective was to discuss the challenges that this patient group presents, and the progress being made to overcome them.

This program was made possible thanks to an independent educational grant from Eli Lilly and Company.

Journal articles and book chapters

08-11-2018 | Non-small cell lung cancer | Article

Risk factors for brain metastases in patients with non–small‐cell lung cancer

Ning An, Wang Jing, Haoyi Wang, Ji Li, Yang Liu, Jinming Yu, Hui Zhu. Cancer Med 2018;7(12): 6357-6364. doi:10.1002/cam4.1865.

21-10-2018 | Non-small cell lung cancer | Article

Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors

Wrona A et al. Cancer Treat Rev 2018; 71: 59–67. doi:10.1016/j.ctrv.2018.10.011.

14-08-2018 | Non-small cell lung cancer | Article

Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI?

Recondo G et al. Nat Rev Clin Oncol 2018. doi:10.1038/s41571-018-0081-4

03-07-2018 | Non-small cell lung cancer | Article

Early stage NSCLC — challenges to implementing ctDNA-based screening and MRD detection

Abbosh C et al. Nat Rev Clin Oncol 2018. doi:10.1038/s41571-018-0058-3

05-06-2018 | Radiotherapy | Article

Safety of combining radiotherapy with immune-checkpoint inhibition

Hwang WL et al. Nat Rev Clin Oncol 2018. doi: 10.1038/s41571-018-0046-7

Case reports and studies

12-04-2016 | Non-small cell lung cancer | Case study | Collection

Navigating the advanced NSCLC patient pathway: New markers and targets - An interactive case study

This is an interactive case study presented by Johan Vansteenkiste, based on a patient case discussed a Springer Healthcare independent symposium at the ELCC 2016.

The purpose of this interactive case study of is for participants to test their knowledge and clinical practices in the management of patients with NSCLC, and gain knowledge of emerging first-line and relapse treatment pathways.

Reference

12-04-2018 | EGFR signalling | Primer | Collection

EGFR signaling in cancer

This downloadable powerpoint slide set includes a variety of high quality illustrations relating to the role of the epidermal growth factor receptor pathway in the pathogenesis and progression of cancer and as a target for anti-cancer therapy.

01-02-2017 | Immunotherapy | Primer | Collection

The fundamentals of cancer immunotherapy

A introductory guide to cancer immunotherapy for non-specialists, focusing primarily on the mechanisms of immune checkpoint inhibition and the role of these agents in anticancer therapy.

08-08-2017 | Non-small cell lung cancer | At a glance | Article

At a glance: The KEYNOTE lung cancer trials

Here is our quick guide to the KEYNOTE trials investigating the anti-PD-1 agent pembrolizumab in the non-small-cell lung cancer setting.

Image Credits